{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:46:09Z","timestamp":1788198369581,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11095-022-03230-0","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:02:44Z","timestamp":1649091764000},"page":"691-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-5787","authenticated-orcid":false,"given":"Pavlos","family":"Chryssafidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4757-324X","authenticated-orcid":false,"given":"Athanasios A.","family":"Tsekouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-0552","authenticated-orcid":false,"given":"Panos","family":"Macheras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"3230_CR1","unstructured":"Dost HF. Der Blutspiegel. Kinetik der Konzentrationsabl\u00e4ufe in der Kreislauffl\u00fcssigkeit. Leipzig: Thieme; 1953."},{"key":"3230_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/jps.2600640921","volume":"64","author":"EG Lovering","year":"1975","unstructured":"Lovering EG, McGilveray IJ, McMillan I, Tostowaryk W. Comparative Bioavailabilities from Truncated Blood Level Curves. J Pharm Sci. 1975;64:1521\u20134. https:\/\/doi.org\/10.1002\/jps.2600640921.","journal-title":"J Pharm Sci"},{"key":"3230_CR3","doi-asserted-by":"crossref","unstructured":"Sugano K. Biopharmaceutics Modeling and Simulations: Theory, Practice, Methods, and Applications. Wiley; 2012.","DOI":"10.1002\/9781118354339"},{"key":"3230_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5599\/admet.923","volume":"9","author":"K Sugano","year":"2021","unstructured":"Sugano K. Lost in modelling and simulation? ADMET DMPK. 2021;9:75\u2013109. https:\/\/doi.org\/10.5599\/admet.923.","journal-title":"ADMET DMPK"},{"key":"3230_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s11095-021-03078-w","volume":"38","author":"P Chryssafidis","year":"2021","unstructured":"Chryssafidis P, Tsekouras AA, Macheras P. Revising pharmacokinetics of oral drug absorption: II bioavailability-bioequivalence considerations. Pharm Res. 2021;38:1345\u201356. https:\/\/doi.org\/10.1007\/s11095-021-03078-w.","journal-title":"Pharm Res"},{"key":"3230_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14366\/usg.15020","volume":"35","author":"P Iranpour","year":"2016","unstructured":"Iranpour P, Lall C, Houshyar R, Helmy M, Yang A, Choi JI, Ward G, Goodwin SC. Altered Doppler flow patterns in cirrhosis patients: an overview. Ultrasonography. 2016;35:3\u201312. https:\/\/doi.org\/10.14366\/usg.15020.","journal-title":"Ultrasonography"},{"key":"3230_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11095-020-02894-w","volume":"37","author":"P Macheras","year":"2020","unstructured":"Macheras P, Chryssafidis P. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical\/Physiological and Finite Absorption Time Concepts. Pharm Res. 2020;37:187. https:\/\/doi.org\/10.1007\/s11095-020-02894-w (Erratum. Pharm Res 2020,37:206. https:\/\/doi.org\/10.1007\/s11095-020-02935-4).","journal-title":"Pharm Res"},{"key":"3230_CR8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1208\/s12248-016-9953-7","volume":"18","author":"A Abuhelwa","year":"2016","unstructured":"Abuhelwa A, Foster DJR, Upton RN. A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time. AAPS J. 2016;18:1322\u201333. https:\/\/doi.org\/10.1208\/s12248-016-9953-7.","journal-title":"AAPS J"},{"key":"3230_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ejps.2013.05.019","volume":"49","author":"E Sj\u00f6gren","year":"2013","unstructured":"Sj\u00f6gren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennern\u00e4s H, Abrahamsson B, Tannergren C. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49:679\u201398. https:\/\/doi.org\/10.1016\/j.ejps.2013.05.019.","journal-title":"Eur J Pharm Sci"},{"key":"3230_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: A systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43:1823\u201337. https:\/\/doi.org\/10.1124\/dmd.115.065920.","journal-title":"Drug Metab Dispos"},{"key":"3230_CR11","unstructured":"Paracetamol oral use, immediate release formulations product-specific bioequivalence guidance (europa.eu)."},{"key":"3230_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40261-015-0320-8","volume":"35","author":"HC Atkinson","year":"2015","unstructured":"Atkinson HC, Stanescu I, Frampton C, Salem II, Beasleyr CPH, Robson R. Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. Clin Drug Investig. 2015;35:625\u201332. https:\/\/doi.org\/10.1007\/s40261-015-0320-8.","journal-title":"Clin Drug Investig"},{"key":"3230_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/0091270002239359","volume":"42","author":"JM Jansat","year":"2002","unstructured":"Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Pharmacokin Pharmacodyn. 2002;42:1303\u201310. https:\/\/doi.org\/10.1177\/0091270002239359.","journal-title":"J Pharmacokin Pharmacodyn"},{"key":"3230_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.2042-7158.1991.tb06688.x","volume":"43","author":"G Ismailos","year":"1991","unstructured":"Ismailos G, Reppas C, Dressman J, Macheras P. Unusual solubility behaviour of cyclosporine A in aqueous media. J Pharm Pharmacol. 1991;43:287\u20139. https:\/\/doi.org\/10.1111\/j.2042-7158.1991.tb06688.x.","journal-title":"J Pharm Pharmacol"},{"key":"3230_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/a:1018922517162","volume":"11","author":"EA Mueller","year":"1994","unstructured":"Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 1994;11:151\u20135. https:\/\/doi.org\/10.1023\/a:1018922517162.","journal-title":"Pharm Res"},{"key":"3230_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","volume":"81","author":"L van Andel","year":"2018","unstructured":"van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol. 2018;81:39\u201346. https:\/\/doi.org\/10.1007\/s00280-017-3455-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3230_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11095-019-2633-4","volume":"36","author":"P Macheras","year":"2019","unstructured":"Macheras P. On an unphysical hypothesis of Bateman equation and its implications for pharmacokinetics. Pharm Res. 2019;36:94. https:\/\/doi.org\/10.1007\/s11095-019-2633-4.","journal-title":"Pharm Res"},{"key":"3230_CR18","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/jps.23476","volume":"102","author":"J Brown","year":"2013","unstructured":"Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefer E, Page R, Nettles RE, Zhu L, Grasela D. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an hiv-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013;102:1742\u201351. https:\/\/doi.org\/10.1002\/jps.23476.","journal-title":"J Pharm Sci"},{"key":"3230_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A Theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320. https:\/\/doi.org\/10.1023\/A:1016212804288.","journal-title":"Pharm Res"},{"key":"3230_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"CY Wu","year":"2005","unstructured":"Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport\/absorption\/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11\u201323. https:\/\/doi.org\/10.1007\/s11095-004-9004-4.","journal-title":"Pharm Res"},{"key":"3230_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijpharm.2014.01.022","volume":"464","author":"P Macheras","year":"2014","unstructured":"Macheras P, Karalis V. A non-binary biopharmaceutical classification of drugs: the \u0391\u0392\u0393system. Int J Pharm. 2014;464:85\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.01.022.","journal-title":"Int J Pharm"},{"key":"3230_CR22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1023\/B:PHAM.0000008037.57884.11","volume":"20","author":"E Rinaki","year":"2003","unstructured":"Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system (QBCS): The central role of dose\/solubility ratio. Pharm Res. 2003;20:1917\u201325. https:\/\/doi.org\/10.1023\/B:PHAM.0000008037.57884.11.","journal-title":"Pharm Res"},{"key":"3230_CR23","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1007\/s11095-012-0815-4","volume":"29","author":"G Charkoftaki","year":"2012","unstructured":"Charkoftaki G, Dokoumetzidis A, Valsami G, Macheras P. Elucidating the role of dose in the biopharmaceutics classification of drugs: The concepts of critical dose, effective in vivo solubility, and dose-dependent BCS. Pharm Res. 2012;29:3188\u201398. https:\/\/doi.org\/10.1007\/s11095-012-0815-4.","journal-title":"Pharm Res"},{"key":"3230_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejps.2018.02.003","volume":"117","author":"P Macheras","year":"2018","unstructured":"Macheras P, Iliadis A, Melagraki G. A reaction-limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs. Eur J Pharm Sci. 2018;117:98\u2013106. https:\/\/doi.org\/10.1016\/j.ejps.2018.02.003.","journal-title":"Eur J Pharm Sci"},{"key":"3230_CR25","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s11095-021-03121-w","volume":"38","author":"AA Tsekouras","year":"2021","unstructured":"Tsekouras AA, Macheras P. Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts. Pharm Res. 2021;38:1635\u20138. https:\/\/doi.org\/10.1007\/s11095-021-03121-w.","journal-title":"Pharm Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03230-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T14:13:40Z","timestamp":1652192020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03230-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3230"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03230-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}